Benchmark restated their speculative buy rating on shares of Anebulo Pharmaceuticals (NASDAQ:ANEB – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $8.00 price objective on the stock.
Anebulo Pharmaceuticals Price Performance
Shares of NASDAQ:ANEB opened at $1.52 on Tuesday. The company’s fifty day moving average price is $1.89 and its 200 day moving average price is $2.10. Anebulo Pharmaceuticals has a 12 month low of $1.46 and a 12 month high of $3.30. The firm has a market capitalization of $39.42 million, a P/E ratio of -5.07 and a beta of -1.00.
Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) last posted its earnings results on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. On average, sell-side analysts anticipate that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
See Also
- Five stocks we like better than Anebulo Pharmaceuticals
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- The Significance of Brokerage Rankings in Stock Selection
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What Are Growth Stocks and Investing in Them
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
